Why Natera (NTRA) Stock Is Up Today

Natera, Inc. (NTRA) will present 20 abstracts at the 2026 ESMO Congress, showcasing its ultrasensitive MRD technology, Signatera Genome, with detection capabilities below 1 part per 10 million. The presentations highlight clinical benefits across various cancer types, including early detection and treatment adjustments. Natera's CMO noted the test's ability to detect ctDNA at unprecedented levels.

Natera (NASDAQ: NTRA) announced 20 abstracts featuring its Signatera Genome technology will be presented at the 2026 ESMO Congress. The technology demonstrated an industry-leading analytical limit of detection (LOD95) below 1 part per million. Key findings include: In the SAGITTARIUS colon cancer trial, Signatera results changed planned treatment for 1 in 3 patients, with 87% of changes being treatment de-escalation.

Natera Inc. (NTRA) and TransCode Therapeutics Inc. (RNAZ) announced a collaboration to enroll patients in a colorectal cancer clinical trial using Natera's Signatera test to identify eligible patients. The trial targets patients at risk of recurrence but with no approved therapies. TransCode's TTX-MC138 aims to inhibit a biomarker linked to metastatic cancers. The trial is part of the PRE-I-SPY program and is registered at clinicaltrials.gov.

TransCode Therapeutics and Natera are collaborating to identify colorectal cancer patients with molecular residual disease (MRD) for a Phase 2a trial of TTX-MC138. The trial, conducted under Quantum Leap Healthcare's PRE-I-SPY program, aims to address the unmet need for treating MRD-positive patients who are disease-free on imaging. TTX-MC138 targets microRNA-10b, a biomarker linked to metastatic cancers. Natera's Signatera test will help streamline patient enrollment.

Natera (NTRA) will use its Signatera MRD test to identify patients for TransCode's Phase 2a TTX-MC138 trial in the PRE-I-SPY program. The trial aims to extend the use of MRD beyond detection. Success depends on positive Phase 2a results and evidence of improved outcomes.

Natera's multi-cancer early detection assay received FDA Breakthrough Device designation. The blood-based test screens for multiple cancers using cell-free DNA, addressing gaps in current screening options. The FDA reviewed data from 12 cancer types, focusing on sensitivity, specificity, and signal origin. The designation accelerates development and review but does not permit marketing. Natera plans to continue collaborating with the FDA.